259 related articles for article (PubMed ID: 28124506)
1. Liraglutide causes large and rapid epicardial fat reduction.
Iacobellis G; Mohseni M; Bianco SD; Banga PK
Obesity (Silver Spring); 2017 Feb; 25(2):311-316. PubMed ID: 28124506
[TBL] [Abstract][Full Text] [Related]
2. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.
Lima-Martínez MM; Paoli M; Rodney M; Balladares N; Contreras M; D'Marco L; Iacobellis G
Endocrine; 2016 Mar; 51(3):448-55. PubMed ID: 26233684
[TBL] [Abstract][Full Text] [Related]
3. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.
Zhao N; Wang X; Wang Y; Yao J; Shi C; Du J; Bai R
J Diabetes Res; 2021; 2021():5578216. PubMed ID: 34825006
[TBL] [Abstract][Full Text] [Related]
5. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
[TBL] [Abstract][Full Text] [Related]
7. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
[TBL] [Abstract][Full Text] [Related]
8. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
Iacobellis G; Gra-Menendez S
Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Feng WH; Bi Y; Li P; Yin TT; Gao CX; Shen SM; Gao LJ; Yang DH; Zhu DL
J Diabetes Investig; 2019 Mar; 10(2):399-407. PubMed ID: 29957886
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
12. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
Inoue K; Maeda N; Kashine S; Fujishima Y; Kozawa J; Hiuge-Shimizu A; Okita K; Imagawa A; Funahashi T; Shimomura I
Cardiovasc Diabetol; 2011 Dec; 10():109. PubMed ID: 22132774
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
17. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Tang A; Rabasa-Lhoret R; Castel H; Wartelle-Bladou C; Gilbert G; Massicotte-Tisluck K; Chartrand G; Olivié D; Julien AS; de Guise J; Soulez G; Chiasson JL
Diabetes Care; 2015 Jul; 38(7):1339-46. PubMed ID: 25813773
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
Vanderheiden A; Harrison LB; Warshauer JT; Adams-Huet B; Li X; Yuan Q; Hulsey K; Dimitrov I; Yokoo T; Jaster AW; Pinho DF; Pedrosa I; Lenkinski RE; Pop LM; Lingvay I
J Clin Endocrinol Metab; 2016 Apr; 101(4):1798-806. PubMed ID: 26909799
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR;
Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
